权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Preclinical Characterization of Drugs in Mouse Model of Lung Cancer

肺癌小鼠模型中药物的临床前表征

基本信息

批准号：
9153828
负责人：
Terry van Dyke
金额：
$ 48.17万
依托单位：
DIVISION OF BASIC SCIENCES - NCI
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9153828
关键词：
Adopted Animals Antineoplastic Agents Bioinformatics Biological Markers Biotechnology Cancer Patient Clinical Clinical Management Clinical Trials Collaborations Complex Data Set Disease Progression Drug Targeting Drug resistance Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Evaluation Studies Experimental Neoplasms Generations Goals Image Malignant Neoplasms Malignant neoplasm of lung Methods Modeling Molecular Non-Small-Cell Lung Carcinoma Nucleic Acids Operative Surgical Procedures Outcome Pharmaceutical Preparations Pharmacologic Substance Phase Relapse Resistance Systems Biology base cancer type clinically relevant cohort comparative efficacy evaluation high throughput technology in vivo insight lung Carcinoma mouse model mutant novel pre-clinical pre-clinical research preclinical evaluation preclinical study protein metabolite therapeutic evaluation tumor

项目摘要

Lung cancer represents the most frequent form of malignancy comprising about 25% of all cancer clinical cased worldwide and being one of few cancer types with steadily increasing occurence. Non-small cell lung carcinomas (NSCLC) are proven to be challenging tumor type for clinical management with frequent re-occurence of drug resistant cancer after initial surgery/therapy and prominent metastatic potential. To gain in-depth insight into the molecular basis of lung carcinoma formation and reasons for drug resistance in relapse phase, the Center for Advanced Preclinical Research successfully adopted and characterized several models of NSCLC. We recently completed studies with a Biotechnology Company that established the utility of their irreversible EGFR inhibitor in the regression of LA harboring the primary L858R EGFR mutant present in patient cancers and of those resistant to first line therapy that express the L858RT790 mutant. This drug has shown similar promise in clinical trials. We completed preclinical studies of a proprietary agent, including PK/PD/Tox and efficacy evaluation, in collaboration with a pharmaceutical company.

肺癌代表最常见的恶性肿瘤形式，占全球所有癌症临床病例的约25%，并且是发生率稳步增加的少数癌症类型之一。非小细胞肺癌（NSCLC）是临床治疗中具有挑战性的肿瘤类型，在初次手术/治疗后经常复发耐药癌症，并具有显著的转移潜力。为了深入了解肺癌形成的分子基础和复发期耐药的原因，高级临床前研究中心成功采用并表征了几种NSCLC模型。我们最近完成了与一家生物技术公司的研究，该公司确定了其不可逆EGFR抑制剂在患者癌症中存在的携带原发性L 858 R EGFR突变体的LA和表达L 858 RT 790突变体的对一线治疗耐药的LA消退中的效用。这种药物在临床试验中也显示出类似的前景。我们与一家制药公司合作完成了一种专利药物的临床前研究，包括PK/PD/Tox和疗效评估。